Fiona Rae

Dr. Fiona Rae

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CBCristina Beer
Cristina Beer
FRFiona Rae
Fiona Rae
Annalese SemmlerAnnalese Semmler
Annalese Semmler
JVJoanne Voisey
Joanne Voisey
Depression continues to be a significant and growing public health concern. In clinical practice, it involves a clinical diagnosis. There is currently no defined or agreed upon biomarker/s for depression that can be readily tested. A biomarker is defined as a biological indicator of normal physiological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention that can be objectively measured and evaluated. Thus, as there is no such marker for depression, there is no objective measure of depression in clinical practice. The discovery of such a biomarker/s would greatly assist clinical practice and potentially lead to an earlier diagnosis of depression and therefore treatment. A biomarker for depression may also assist in determining response to medication. This is of particular importance as not all patients prescribed with medication will respond, which is referred to as medication resistance. The advent of pharmacogenomics in recent years holds promise to target treatment in depression, particularly in cases of medication resistance. The role of pharmacogenomics in routine depression management within clinical practice remains to be fully established. Equally so, the use of pharmaceutical grade nutrients known as nutraceuticals in the treatment of depression in the clinical practice setting is largely unknown, albeit frequently self-prescribed by patients. Whether nutraceuticals have a role in not only depression treatment but also in potentially modifying the biomarkers of depression has yet to be proven. The aim of this review is to highlight the potential biomarkers for the diagnosis, prediction, and medication response of depression.

6 July 2026 in Journal of Child Neurology
Verified
Journal Article
Open access
JFJennifer Fairthorne
Jennifer Fairthorne
FRFiona Rae
Fiona Rae
AGAbha Gupta
Abha Gupta
JVJoanne Voisey
Joanne Voisey
Autism spectrum disorder (autism) is diagnosed by persistent deficits in communication and social interaction, along with restricted, repetitive behaviors or interests. About a third of children with autism appear to develop normally but subsequently regress and eventually present with autism. This condition is termed regressive autism and the associated regression termed autistic regression . Children undergoing autistic regression after 2 years are described as having childhood disintegrative disorder . We aimed to conduct a scoping review to identify and summarize the genetic etiologies and correlates of regressive autism and childhood disintegrative disorder. Using key words, we searched 4 databases for papers published from January 2010 to February 2024. Thirty-two papers were retained. Nearly 90 genetic variants were associated with these conditions, and some treatments improved proband functioning. Epigenetic involvement, immune dysfunction and toxicant exposures were related to autistic regression while recurring comorbidities were inflammatory bowel disease, fever and mitochondrial disease. Regressive autism is variably defined, impeding research. The development of a precise definition is needed. Furthermore, regressive autism and its subtype, childhood disintegrative disorder, have many causes, which means that developing biomarkers and endotypes to explore etiologies would likely pay dividends. Because of the increasing prevalence of autism, regressive autism is no longer a rare condition, emphasizing the grave need to promote research in this area. Expected benefits might be improved outcomes for those affected and genetic counselling for at-risk family members. Longer-term benefits might be reduced prevalence, less emotional and financial burdens for families, and lower fiscal burdens for governments.

26 August 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
CBCristina Beer
Cristina Beer
FRFiona Rae
Fiona Rae
MWMikayla Watt
Mikayla Watt
MTMaciej Trzaskowski
Maciej Trzaskowski
CYClarissa Yates
Clarissa Yates
JVJoanne Voisey
Joanne Voisey
Background & Aims: One-carbon metabolism plays a central role in neurotransmitter synthesis, methylation capacity, and neurobiological resilience. Variants in the methylenetetrahydrofolate reductase (MTHFR) gene can reduce enzymatic activity, affecting folate- and methionine-cycle functions and potentially influencing biological pathways relevant to mood and anxiety disorders. Personalised nutraceutical treatment strategies, particularly those addressing methylation capacity through targeted B-vitamin, folate, and adjunctive metabolic interventions are increasingly implemented in integrative clinical practice, yet evidence regarding their clinical outcomes remains limited. Methods: We conducted a retrospective cohort study of 50 adults attending an integrative general practice clinic for anxiety and/or depression. All received personalised nutraceutical treatment informed by clinical assessment, laboratory testing and, for 37/50 patients, MTHFR genotyping. Psychological distress was measured using the Kessler-10 (K10) scale at baseline and approximately three months later. Secondary analyses evaluated whether outcomes differed by MTHFR genotype, whether specific supplements (e.g., L-methylfolate and SAMe) were associated with greater improvement, whether biomarker changes correlated with symptom change, and the safety/tolerability profile. Results: Across the full cohort, mean K10 scores significantly decreased by four points over the treatment period, with 72% of patients showing clinical improvement. Reductions in psychological distress were seen across all MTHFR genotypes, including individuals with homozygous variant genotypes. Supplement-specific analyses showed improvement among those receiving methylfolate or SAMe, although the differences were not statistically significant. Following nutraceutical treatment, biomarker analyses demonstrated significant increases in serum vitamin B12 and modest reductions in homocysteine, but biomarker shifts did not correlate strongly with K10 change. No serious adverse events or clinically significant abnormalities in liver or renal function were identified. Conclusions: In this real-world primary care cohort, personalised nutraceutical treatment, grounded in one-carbon metabolism support and applied alongside usual care, was associated with clinically meaningful reductions in psychological distress. Outcomes were comparable across MTHFR genotypes when treatments were appropriately tailored, suggesting that genotype and biomarker-informed nutraceutical strategies may mitigate potential metabolic disadvantages. These findings support further controlled research into precision nutraceutical psychiatry for anxiety and depression. Secondary analyses of genotype subgroup, specific supplements, and biomarker–outcome associations are reported alongside Benjamini–Hochberg FDR-adjusted p-values and should be interpreted as hypothesis-generating.

Verified
Journal Article
Open access
PDF file
CBCristina Beer
Cristina Beer
FRFiona Rae
Fiona Rae
MWMikayla Watt
Mikayla Watt
Annalese SemmlerAnnalese Semmler
Annalese Semmler
JVJoanne Voisey
Joanne Voisey
Treatment-resistant mental health conditions are common in primary care and challenging for clinicians. Trial-and-error prescribing can prolong morbidity and increase adverse drug reactions (ADRs). Pharmacogenomic (PGx) testing enables individualised prescribing by identifying gene–drug interactions affecting psychotropic response. Thirty adults with treatment-resistant mental health conditions underwent PGx testing using a commercial panel (one lost to follow-up [n = 29]). Patients received PGx-guided treatment (n = 8) or standard care (n = 21). Phenotypes were assigned per CPIC and DPWG guidelines, with prescribing guided by clinical experience where guidelines were unavailable. Medication histories were reviewed for gene–drug concordance, ADRs, and treatment failures. Clinical improvement at eight weeks was defined as “marked” or “moderate” improvement and/or ADR resolution. Actionable genotypes were common, particularly CYP2D6 (27.5% poor/intermediate drug metabolising phenotype) and CYP2C19 (37.9%). Guideline-actionable gene–drug interactions occurred in 37% of patients, and eleven patients possessed actionable phenotype at multiple loci. Gene–drug interactions were identified in nine patients and guidance was fully implemented in six. Clinical benefit at 8 weeks was achieved in 6/8 patients with genotype-guided changes versus 8/21 receiving standard care. PGx-guided prescribing may support improved antidepressant response and tolerability while reducing trial-and-error prescribing for treatment-resistant patients in primary care.

12 June 2026 in CNS Oncology
Verified
Journal Article
Open access
DEDylan Evans
Dylan Evans
JVJoanne Voisey
Joanne Voisey
JGJenni Gunter
Jenni Gunter
FRFiona Rae
Fiona Rae
Glioblastoma (GBM) is the most aggressive and biologically heterogeneous tumor of the central nervous system, associated with dismal prognosis and frequent recurrence. Amplification of the epidermal growth factor receptor (EGFR) and EGFRvIII mutation are common alterations, yet their prognostic significance remains unclear. This systematic review evaluated whether clinical evidence supports a predictive association between EGFR amplification or EGFRvIII mutation and response to EGFR-targeted therapy in adults with recurrent GBM. PubMed, Embase and the Cochrane Library were searched (2010–2025) for studies of adults with recurrent GBM treated with EGFR-targeted therapies, with outcomes stratified by EGFR amplification and/or EGFRvIII. Screening, data extraction and risk-of-bias assessment were performed independently. Twelve studies (565 patients) met inclusion criteria. EGFR amplification was assessed in 11 studies and EGFRvIII in six using FISH, qPCR, RT-PCR, or NGS. Median overall survival ranged from 5.7 to 10.3 months and progression-free survival from 1.7 to 6.0 months, with no consistent survival benefit observed. EGFR amplification and EGFRvIII mutation have not demonstrated reliable predictive value for EGFR-targeted therapy in recurrent GBM. The available evidence is largely derived from heterogeneous, single-arm studies, limiting robust assessment of biomarker specific treatment response and therefore these alterations are not recommended to be used to guide off-trial treatment decisions in recurrent GBM. Protocol Registration: www.crd.york.ac.uk/prospero identifier is CRD420251071466.